Terazosin is an alpha-adrenergic blocker indicated for the treatment of signs and symptoms of benign prostatic hyperplasia (BPH), among other approved uses. It is available as capsules and oral solution. MedsAcross supplies Terazosin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
TEZRULY TM (terazosin) is an alpha-1 adrenoceptor antagonist indicated for: The treatment of signs and symptoms of benign prostatic hyperplasia (BPH). The treatment of hypertension alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarction.
Source: US FDA prescribing information
Benign Prostatic Hyperplasia The symptoms associated with benign prostatic hyperplasia (BPH) are related to bladder outlet obstruction, which is comprised of two underlying components: static and dynamic. The static component is related to an increase in prostate size caused, in part by a proliferation of smooth muscle cells in the prostatic stroma. However, the severity of BPH symptoms and the degree of urethral obstruction do not correlate well with the size of the prostate. The dynamic component is a function of an increase in smooth muscle tone in the prostate and bladder neck. The degree of tone in this area is mediated by the alpha-1-adrenoceptors, which is reent in high density in the prostate stroma, prostatic capsule, prostatic urethra, and bladder neck.
Source: US FDA prescribing information
For the treatment of BPH: Initiate therapy at 1 mg orally once daily at bedtime. Titrate the dose upwards step-wise from 2 mg to 10 mg once daily. Doses of 10 mg once daily are generally required for a clinical response. Data is insufficient to support doses greater than 20 mg once daily. For the treatment hypertension: Initiate therapy at 1 mg orally once daily at bedtime. Usual recommended dose range is 1 mg to 5 mg once daily. If response is substantially diminished at 24 hours, increase the dose or use twice daily. Dose may be titrated as needed up to 20 mg once daily. If terazosin is discontinued for more than a few days, restart using the initial dosing regimen.
Source: US FDA prescribing information
TEZRULY is contraindicated in patients known to be hypersensitive to terazosin or any component of TEZRULY. Hypersensitivity to terazosin hydrochloride or any other ingredient in TEZRULY.
Source: US FDA prescribing information
Syncope and “First-dose” Effect: Advise patients about the possibility of symptoms related to postural hypotension and to avoid situations where injury could result should syncope occur, especially when starting TEZRULY. Orthostatic Hypotension: Dizziness, lightheadedness, and palpitations can occur with use of TEZRULY. Advise patients to take their first dose of TEZRULY at bedtime and to avoid driving or hazardous tasks for 12 hours after the first dose, after a dosage increase, and after interruption of therapy when treatment is resumed. Risk of Hypotension with Concomitant Use of Other Antihypertensive Agents and Phospodiesterase Type 5 Inhibitors (PDE5-I): Concomitant administration of TEZRULY with antihypertensives or phosphodiesterase-5 (PDE-5) inhibitors can result in additive blood pressure lowering effects and symptomatic hypotension.
Source: US FDA prescribing information
The following clinically significant adverse reactions are described elsewhere in the labeling: Syncope and ‘‘First-dose’’ Effect Orthostatic Hypotension Priapism Intraoperative Floppy Iris Syndrome In treatment of BPH, the most common adverse reactions (≥1% of patients and at a higher incidence than placebo) were asthenia, flu syndrome, postural hypotension, nausea, somnolence, vertigo, dyspnea, nasal congestion/rhinitis, blurred vision/amblyopia and erectile dysfunction.
Source: US FDA prescribing information
Co-administration of verapamil with terazosin increases the systemic exposure of terazosin, which may increase the risk of hypotenstion. To reduce the risk of hypotension, dosage reduction and re-titration of either agent may be necessary. Co-administration of verapamil with terazosin increases the systemic exposure of terazosin and may lead to hypotension. Dosage reduction and re-titration of either agent may be necessary.
Source: US FDA prescribing information
Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
5 presentations of Terazosin, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Terazosin 2 mg capsuleOralGeneric name | — | US FDA | Available on request |
| Terazosin 5 mg capsuleOralGeneric name | — | US FDA | Available on request |
| Terazosin 1 mg capsuleOralGeneric name | — | US FDA | Available on request |
| Terazosin 10 mg capsuleOralGeneric name | — | US FDA | Available on request |
| Tezruly 1 mg/mL oral solutionOral | ANI Pharmaceuticals | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 7 August 1987 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Terazosin in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 5 presentations of Terazosin and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Terazosin, including Tezruly.
Yes. The US FDA first approved Terazosin on 7 August 1987, according to Drugs@FDA.
No listed presentation of Terazosin is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Terazosin is classified under ATC code G04CA03 (Terazosin).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.